Sartorius Stedim stock context builds from parent Sartorius valuation

Sartorius Stedim stock draws investor attention through its link to Sartorius AG, whose shares recently traded around EUR183.60 on Xetra as of August 18, 2026, providing a valuation benchmark for the bioprocessing group.

Sartorius Stedim Biotech SA (ISIN FR0013154002) is closely tied to the broader Sartorius group, and investors in Sartorius Stedim stock often look at the valuation of Sartorius AG as a reference point for the bioprocessing franchise as of August 18, 2026.

Sartorius AG recent share level and valuation reference

Per a detailed market-data overview, Sartorius AG shares last closed at EUR183.60 on August 18, 2026 on their primary German listing, giving investors a concrete current level for valuation discussions within the Sartorius group. Recent reporting describes the stock as trading close to this EUR183.60 level while investors assess demand for bioprocessing equipment and services in the pharmaceutical and biotech sectors.

Additional real-time quote information compiled from market portals indicates that Sartorius AG was recently seen at EUR182.20 in Tradegate quotes on August 19, 2026, compared with a last close price of EUR228.90, highlighting that the current real-time indication is EUR46.70 below the most recent recorded close for the stock.

Analyst consensus and upside potential for the group

According to an analyst consensus overview, the average target price for Sartorius AG stands at EUR265.95, compared with the most recently stated last close price of EUR228.90, implying an indicated upside of EUR37.05 per share from that close based on the current consensus target. This consensus snapshot also shows a real-time Tradegate price of EUR182.20 on August 19, 2026, which sits EUR83.75 below the EUR265.95 average target, underscoring that analysts still see considerable potential in the broader Sartorius equity story if the company executes on its bioprocessing growth plans.

For investors in Sartorius Stedim stock, this analyst positioning on the parent company offers a useful benchmark, as Sartorius Stedim Biotech SA represents the biologics-focused bioprocessing arm of the group and participates in similar end-market trends in pharmaceutical manufacturing and biotech production.

Group context for Sartorius Stedim Biotech SA

While the latest specific quarterly figures for Sartorius Stedim Biotech SA are not contained in the same day-filtered source set, the current valuation and consensus data for Sartorius AG as of August 19, 2026 provide an indicative framework for thinking about Sartorius Stedim stock. With the parent company shares trading around the low EUR180s and a consensus target near EUR266, the implied valuation gap suggests that the market is balancing short-term cyclical concerns in bioprocessing with longer-term expectations for growth in biologics manufacturing capacity.

Historically, Sartorius group revenue has been driven by demand for filtration systems, bioreactors, and single-use solutions that support biopharmaceutical production. Sartorius Stedim Biotech SA is central to this offering, and investor sentiment toward the group often reflects expectations for continued expansion of biologic drug pipelines and vaccine production volumes worldwide.

Representative product focus: single-use bioreactors

One representative product area for Sartorius Stedim Biotech SA is its portfolio of single-use bioreactors used in upstream bioprocessing. These systems allow biotech and pharmaceutical manufacturers to produce monoclonal antibodies, vaccines, and other biologics while reducing cleaning validation time and increasing flexibility across different production campaigns.

Shares context and investor perspective

Even though a live, directly quoted price for Sartorius Stedim Biotech SA shares is not explicitly available in the current day-filtered sources, the recent EUR183.60 close for Sartorius AG as of August 18, 2026, combined with the EUR265.95 consensus target, offers investors a practical framework for assessing how Sartorius Stedim stock might be valued relative to the broader group as market conditions in bioprocessing evolve.

Read more

More on Sartorius group valuation

Fact box

Company: Sartorius Stedim Biotech SA

ISIN: FR0013154002

Ticker: not specified

Exchange: Euronext Paris

Sector / Industry: Health care equipment and supplies, bioprocessing

Index membership: not specified